Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04659044
Title Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications

mantle cell lymphoma

marginal zone B-cell lymphoma

follicular lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax

Rituximab Hyaluronidase + Venetoclax

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.